Candin for the Treatment of Common Warts

Completed · Phase 3 · Has a placebo group

Conditions studied: Common Warts (Verruca Vulgaris)

In brief

The goal of this clinical trial is to compare outcome in healthy subjects 12 years of age and older with at least 3, but no more than 20, common warts (Verruca vulgaris) following treatment with Candin or placebo. The main questions it aims to answer are: * does treatment with Candin result in better clearance of warts than placebo * how many injections are required to result in wart clearance Participants will * have one wart selected for injection every two weeks until clearance * return 12 weeks after wart clearance for assessment of durability of response

Key facts

Study ID

NCT05889845

Run by

Nielsen BioSciences, Inc.

People needed

330

Starts

2025-01-22

Expected to finish

2025-08-27

Last updated by the study team

2025-09-05

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 3, but not more than 20 common warts (Verruca vulgaris)
• Willing to agree to use adequate contraception methods during the study

You may not qualify if…

• Systemic or localized diseases, conditions, or medications that could interfere with the assessment of safety or efficacy or that compromise immune function
• Candin delayed type hypersensitivity reaction test wheal sized < 5 mm or > 25 mm at the Baseline Visit
• History of keloid formation
• Prior treatment of common warts with liquid nitrogen, carbon dioxide, electrodesiccation, laser, surgery, salicylic acid, etc., that, in the Investigator's opinion, does not exhibit complete healing from the treatment
• Treatment with immunotherapy (e.g., diphenylcyclopropenone [DPCP], dinitrochlorobenzene [DNCB], or other), imiquimod, 5-fluorouracil, bleomycin, or podophyllin within 12 weeks of the Baseline Visit or during the study
• Prior treatment with Candida albicans within 12 weeks of the Baseline Visit or during the study
• Systemic treatment with an immunosuppressive drug during the study or in the 6 months or 5 half lives prior to the Baseline Visit or during the study (e.g., azathioprine, 6 mercaptopurine, methotrexate, infliximab, adalimumab, etanercept, systemic steroids [topical or inhaled steroids are acceptable]).
• Use of cantharidin or an investigational agent or device within the 30 days prior to the Baseline Visit or during the study

Where it is running

• Cahaba Dermatology — Birmingham, Alabama, United States
• Arkansas Pediatric Clinic — Bryant, Arkansas, United States
• Johnson Dermatology — Fort Smith, Arkansas, United States
• Dermatology Clinic of Arkansas — Hot Springs, Arkansas, United States
• Velocity Clinical La Mesa — La Mesa, California, United States
• Long Beach Research — Long Beach, California, United States
• Integrative Skin Research — Sacramento, California, United States
• Velocity Clinical Englewood — Englewood, Colorado, United States
• Kaminska Dermatology — Chicago, Illinois, United States
• Integrated Dermatology of Newton-Brighton — Brighton, Massachusetts, United States
• Hamzavi Dermatology — Fort Gratiot, Michigan, United States
• Schlessinger MD — Omaha, Nebraska, United States
• Advocare Berlin Medical Associates — Berlin, New Jersey, United States
• Bryn Mawr Health Center — Newtown Square, Pennsylvania, United States
• Velocity Clinical Spartanburg — Spartanburg, South Carolina, United States
• DermResearch — Austin, Texas, United States
• Austin Institute for Clinical Research — Pflugerville, Texas, United States
• Velocity Clinical Hampton — Hampton, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.